INDUSTRY OVERVIEW
The Radiopharmaceuticals in Nuclear Medicine is Growing at 21% and is expected to reach 45Billion by 2031. Below mentioned are some of the dynamics shaping the Radiopharmaceuticals in Nuclear Medicine .Radiopharmaceuticals in Nuclear Medicine Market Size in (USD Billion) CAGR Growth Rate 21%
| Study Period | 2019-2031 |
| Market Size (2023): | 15Billion |
| Market Size (2031): | 45Billion |
| CAGR (2023 - 2031): | 21% |
| Fastest Growing Region | Asia Pacific |
| Dominating Region | North America |
www.htfmarketinsights.com
Radiopharmaceuticals are radioactive compounds that have a bound radionuclide in their structure, whose purpose is directing the radionuclide to a location to be treated or to obtain images. Nuclear medications, also known as radiopharmaceuticals, are used to treat lymphoma and bone metastases. Nuclear medicines such as F-18, Tc-99, Ga-67, and I-123 are used in diagnostic operations, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are employed in therapeutic procedures. In comparison to chemotherapy, the convenience of treatment using minimally invasive approaches attracts more people to radiopharmaceuticals. The radiopharmaceuticals industry is driven by the rising number of cardiac patients and the development of clear imaging techniques using diagnostic equipment such as PET and SPECT. Supply constraints, logistical challenges, and a scarcity of skilled medical professionals are among the problems limiting the market's growth.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- Rising Incidence As Well As Prevalence Of Target Conditions
- Huge Development Of Alpha-radioimmunotherapy-based Targeted Cancer Treatments
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- Regulatory Approval & Cost Of Production
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- Advances in cancer treatment & diagnostics
Market Opportunities:
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- Use Of Radiopharmaceuticals In Neurological Applications
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- Diagnostic
- Therapeutic
- Imaging
- Targeted
Radiopharmaceuticals in Nuclear Medicine Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Healthcare
- Oncology
- Diagnostics
- Pharmaceuticals
- Medical research
Radiopharmaceuticals in Nuclear Medicine Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The North America currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, Asia Pacific is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Asia Pacific
Dominating Region
North America
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- Cardinal Health (United States)
- GE Healthcare (United States)
- Curium (France)
- Lantheus Medical Imaging (United States)
- Bayer AG (Germany)
- Bracco Imaging (Italy)
- Eczacýbaþý-Monrol Nuclear Products (Turkey)
- Nordion (Canada)
- Advanced Accelerator Applications (France)
- NTP Radioisotopes (South Africa)
Radiopharmaceuticals in Nuclear Medicine Market Segmentation by Players
www.htfmarketinsights.com
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2023 |
|
Based Year Market Size (2023) |
15Billion |
|
Historical Period |
2019 to 2023 |
|
CAGR (2023 to 2031) |
21% |
|
Forecast Period |
2023 to 2031 |
|
Forecasted Period Market Size (2031) |
45Billion |
|
Scope of the Report |
Segmentation by Type Diagnostic, Therapeutic, Imaging, Targeted, Segmentation by Application Healthcare, Oncology, Diagnostics, Pharmaceuticals, Medical research, Sales Channel |
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
Cardinal Health (United States), GE Healthcare (United States), Curium (France), Lantheus Medical Imaging (United States), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), NTP Radioisotopes (South Africa), |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
Radiopharmaceuticals in Nuclear Medicine - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Radiopharmaceuticals in Nuclear Medicine Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Radiopharmaceuticals in Nuclear Medicine Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 Rising incidence as well as prevalence of target conditions
- 3.1.2 Huge Development of alpha-radioimmunotherapy-based targeted cancer treatments
-
3.2 Available Opportunities
- 3.2.1 Use of radiopharmaceuticals in neurological applications
-
3.3 Influencing Trends
- 3.3.1 Advances in cancer treatment & diagnostics
-
3.4 Challenges
- 3.4.1 Regulatory approval & cost of production
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Radiopharmaceuticals in Nuclear Medicine Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Radiopharmaceuticals in Nuclear Medicine Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
- 4.9 Impact of Tariff War
Chapter 5: Radiopharmaceuticals in Nuclear Medicine : Competition Benchmarking & Performance Evaluation
- 5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Radiopharmaceuticals in Nuclear Medicine Revenue 2023
- 5.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Manufacturers (2023)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 Strategic Group Analysis
- 5.6 5C’s Analysis
Chapter 6: Global Radiopharmaceuticals in Nuclear Medicine Market: Company Profiles
- 6.1 Cardinal Health (United States)
- 6.1.1 Cardinal Health (United States) Company Overview
- 6.1.2 Cardinal Health (United States) Product/Service Portfolio & Specifications
- 6.1.3 Cardinal Health (United States) Key Financial Metrics
- 6.1.4 Cardinal Health (United States) SWOT Analysis
- 6.1.5 Cardinal Health (United States) Development Activities
- 6.2 GE Healthcare (United States)
- 6.3 Curium (France)
- 6.4 Lantheus Medical Imaging (United States)
- 6.5 Bayer AG (Germany)
- 6.6 Bracco Imaging (Italy)
- 6.7 Eczacýbaþý-Monrol Nuclear Products (Turkey)
- 6.8 Nordion (Canada)
- 6.9 Advanced Accelerator Applications (France)
- 6.10 NTP Radioisotopes (South Africa)
- 6.11
- 6.12
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Radiopharmaceuticals in Nuclear Medicine by Type & Application (2019-2031)
-
7.1 Global Radiopharmaceuticals in Nuclear Medicine Market Revenue Analysis (USD Million) by Type (2019-2023)
- 7.1.1 Diagnostic
- 7.1.2 Therapeutic
- 7.1.3 Imaging
- 7.1.4 Targeted
- 7.1.5 Biologic
-
7.2 Global Radiopharmaceuticals in Nuclear Medicine Market Revenue Analysis (USD Million) by Application (2019-2023)
- 7.2.1 Healthcare
- 7.2.2 Oncology
- 7.2.3 Diagnostics
- 7.2.4 Pharmaceuticals
- 7.2.5 Medical Research
- 7.3 Global Radiopharmaceuticals in Nuclear Medicine Market Revenue Analysis (USD Million) by Type (2023-2031)
- 7.4 Global Radiopharmaceuticals in Nuclear Medicine Market Revenue Analysis (USD Million) by Application (2023-2031)
Chapter 8 : North America Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 8.1 North America Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 8.2.1 Diagnostic
- 8.2.2 Therapeutic
- 8.2.3 Imaging
- 8.2.4 Targeted
- 8.2.5 Biologic
-
8.3 North America Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 8.3.1 Healthcare
- 8.3.2 Oncology
- 8.3.3 Diagnostics
- 8.3.4 Pharmaceuticals
- 8.3.5 Medical Research
- 8.4 North America Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 8.5 North America Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 8.6 North America Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 9.1 LATAM Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 9.2.1 Diagnostic
- 9.2.2 Therapeutic
- 9.2.3 Imaging
- 9.2.4 Targeted
- 9.2.5 Biologic
-
9.3 LATAM Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 9.3.1 Healthcare
- 9.3.2 Oncology
- 9.3.3 Diagnostics
- 9.3.4 Pharmaceuticals
- 9.3.5 Medical Research
- 9.4 LATAM Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 9.5 LATAM Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 9.6 LATAM Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 10 : West Europe Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 10.1 West Europe Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 10.2.1 Diagnostic
- 10.2.2 Therapeutic
- 10.2.3 Imaging
- 10.2.4 Targeted
- 10.2.5 Biologic
-
10.3 West Europe Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 10.3.1 Healthcare
- 10.3.2 Oncology
- 10.3.3 Diagnostics
- 10.3.4 Pharmaceuticals
- 10.3.5 Medical Research
- 10.4 West Europe Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 10.5 West Europe Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 10.6 West Europe Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 11 : Central & Eastern Europe Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 11.2.1 Diagnostic
- 11.2.2 Therapeutic
- 11.2.3 Imaging
- 11.2.4 Targeted
- 11.2.5 Biologic
-
11.3 Central & Eastern Europe Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 11.3.1 Healthcare
- 11.3.2 Oncology
- 11.3.3 Diagnostics
- 11.3.4 Pharmaceuticals
- 11.3.5 Medical Research
- 11.4 Central & Eastern Europe Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 11.5 Central & Eastern Europe Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 11.6 Central & Eastern Europe Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 12 : Northern Europe Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 12.2.1 Diagnostic
- 12.2.2 Therapeutic
- 12.2.3 Imaging
- 12.2.4 Targeted
- 12.2.5 Biologic
-
12.3 Northern Europe Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 12.3.1 Healthcare
- 12.3.2 Oncology
- 12.3.3 Diagnostics
- 12.3.4 Pharmaceuticals
- 12.3.5 Medical Research
- 12.4 Northern Europe Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 12.5 Northern Europe Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 12.6 Northern Europe Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 13 : Southern Europe Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 13.2.1 Diagnostic
- 13.2.2 Therapeutic
- 13.2.3 Imaging
- 13.2.4 Targeted
- 13.2.5 Biologic
-
13.3 Southern Europe Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 13.3.1 Healthcare
- 13.3.2 Oncology
- 13.3.3 Diagnostics
- 13.3.4 Pharmaceuticals
- 13.3.5 Medical Research
- 13.4 Southern Europe Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 13.5 Southern Europe Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 13.6 Southern Europe Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 14 : East Asia Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 14.1 East Asia Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 14.2.1 Diagnostic
- 14.2.2 Therapeutic
- 14.2.3 Imaging
- 14.2.4 Targeted
- 14.2.5 Biologic
-
14.3 East Asia Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 14.3.1 Healthcare
- 14.3.2 Oncology
- 14.3.3 Diagnostics
- 14.3.4 Pharmaceuticals
- 14.3.5 Medical Research
- 14.4 East Asia Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 14.5 East Asia Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 14.6 East Asia Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 15 : Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 15.2.1 Diagnostic
- 15.2.2 Therapeutic
- 15.2.3 Imaging
- 15.2.4 Targeted
- 15.2.5 Biologic
-
15.3 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 15.3.1 Healthcare
- 15.3.2 Oncology
- 15.3.3 Diagnostics
- 15.3.4 Pharmaceuticals
- 15.3.5 Medical Research
- 15.4 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 15.5 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 15.6 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 16 : South Asia Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 16.1 South Asia Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 16.2.1 Diagnostic
- 16.2.2 Therapeutic
- 16.2.3 Imaging
- 16.2.4 Targeted
- 16.2.5 Biologic
-
16.3 South Asia Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 16.3.1 Healthcare
- 16.3.2 Oncology
- 16.3.3 Diagnostics
- 16.3.4 Pharmaceuticals
- 16.3.5 Medical Research
- 16.4 South Asia Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 16.5 South Asia Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 16.6 South Asia Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 17 : Central Asia Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 17.1 Central Asia Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 17.2.1 Diagnostic
- 17.2.2 Therapeutic
- 17.2.3 Imaging
- 17.2.4 Targeted
- 17.2.5 Biologic
-
17.3 Central Asia Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 17.3.1 Healthcare
- 17.3.2 Oncology
- 17.3.3 Diagnostics
- 17.3.4 Pharmaceuticals
- 17.3.5 Medical Research
- 17.4 Central Asia Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 17.5 Central Asia Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 17.6 Central Asia Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 18 : Oceania Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 18.1 Oceania Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 18.2.1 Diagnostic
- 18.2.2 Therapeutic
- 18.2.3 Imaging
- 18.2.4 Targeted
- 18.2.5 Biologic
-
18.3 Oceania Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 18.3.1 Healthcare
- 18.3.2 Oncology
- 18.3.3 Diagnostics
- 18.3.4 Pharmaceuticals
- 18.3.5 Medical Research
- 18.4 Oceania Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 18.5 Oceania Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 18.6 Oceania Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 19 : MEA Radiopharmaceuticals in Nuclear Medicine Market Breakdown by Country, Type & Application
- 19.1 MEA Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 19.2.1 Diagnostic
- 19.2.2 Therapeutic
- 19.2.3 Imaging
- 19.2.4 Targeted
- 19.2.5 Biologic
-
19.3 MEA Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 19.3.1 Healthcare
- 19.3.2 Oncology
- 19.3.3 Diagnostics
- 19.3.4 Pharmaceuticals
- 19.3.5 Medical Research
- 19.4 MEA Radiopharmaceuticals in Nuclear Medicine Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 19.5 MEA Radiopharmaceuticals in Nuclear Medicine Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 19.6 MEA Radiopharmaceuticals in Nuclear Medicine Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Radiopharmaceuticals in Nuclear Medicine market is estimated to derive a market size of 45Billion by 2031.
The Radiopharmaceuticals in Nuclear Medicine Market is growing at a CAGR of 21% over the forecasted period 2023 - 2031.
Advances In Cancer Treatment & Diagnostics are seen to make big Impact on Radiopharmaceuticals in Nuclear Medicine Market Growth.
The leaders in the Global Radiopharmaceuticals in Nuclear Medicine Market such as Cardinal Health (United States), GE Healthcare (United States), Curium (France), Lantheus Medical Imaging (United States), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), NTP Radioisotopes (South Africa), , are targeting innovative and differentiated growth drivers some of them are Rising Incidence As Well As Prevalence Of Target Conditions,,
Huge Development Of Alpha-radioimmunotherapy-based Targeted Cancer Treatments,,
Business transformation in Radiopharmaceuticals in Nuclear Medicine Market has taken hold due to the confluence of several important triggers, some of them are Regulatory Approval & Cost Of Production.
Some of the opportunities that Analyst at HTF MI have identified in Radiopharmaceuticals in Nuclear Medicine Market are:
- Use Of Radiopharmaceuticals In Neurological Applications
Cardinal Health (United States), GE Healthcare (United States), Curium (France), Lantheus Medical Imaging (United States), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), NTP Radioisotopes (South Africa), , are the major operating companies profiled in Radiopharmaceuticals in Nuclear Medicine market study.
The Global Radiopharmaceuticals in Nuclear Medicine Market Study is Broken down by applications such as Healthcare, Oncology, Diagnostics, Pharmaceuticals, Medical research.
The Global Radiopharmaceuticals in Nuclear Medicine Market Study is segmented by Diagnostic, Therapeutic, Imaging, Targeted, Biologic.
The Global Radiopharmaceuticals in Nuclear Medicine Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
The Radiopharmaceuticals in Nuclear Medicine Market is studied from 2019 - 2031.
Radiopharmaceuticals are radioactive compounds that have a bound radionuclide in their structure, whose purpose is directing the radionuclide to a location to be treated or to obtain images. Nuclear medications, also known as radiopharmaceuticals, are used to treat lymphoma and bone metastases. Nuclear medicines such as F-18, Tc-99, Ga-67, and I-123 are used in diagnostic operations, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are employed in therapeutic procedures. In comparison to chemotherapy, the convenience of treatment using minimally invasive approaches attracts more people to radiopharmaceuticals. The radiopharmaceuticals industry is driven by the rising number of cardiac patients and the development of clear imaging techniques using diagnostic equipment such as PET and SPECT. Supply constraints, logistical challenges, and a scarcity of skilled medical professionals are among the problems limiting the market's growth.
